trending Market Intelligence /marketintelligence/en/news-insights/trending/cu0m_trknchgkxwgi7d94g2 content esgSubNav
In This List

Allergan's nonsurgical fat removal procedure cleared by US FDA for expanded use

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Allergan's nonsurgical fat removal procedure cleared by US FDA for expanded use

The U.S. Food and Drug Administration cleared CoolSculpting, Allergan PLC's nonsurgical fat removal procedure, to treat the area below the jawline.

The approval also includes the expanded use of CoolSculpting to treat patients with a body mass index of up to 46.2 in the areas below their chin and jawline.

The Irish company said the regulator's approval was backed by the results of a 22-week clinical study in which CoolScupting reduced fat layer thickness by an average of 33% after two treatments.

Allergan's CoolSculpting selectively reduces unwanted fat through a patented cooling technology that gently cools targeted fat cells in the body, triggering a natural and controlled elimination of fat cells.